For the reporting of adverse events or other safety-relevant information involving Astellas products, please visit our Contact Us page.
Astellas is a pharmaceutical company committed to making a meaningful difference to people’s everyday lives. Our role is to answer the unmet needs of patients across the world and the many healthcare professionals and caregivers around them.
To deliver against Astellas’ global mission, our Astellas EMEA (Astellas Pharma Europe Limited, APEL) team work ethically and transparently across the region with external audiences, such as media, professional organisations, politicians, industry groups and the public.
Our social media channels help us connect with these and other stakeholders across EMEA so that they can discover more information on aspects of our work relevant to them, and keep up to date on the latest company news.
While content posted on our social media represents our views, please be aware that the views expressed by others on our channels are not the views of Astellas EMEA, its employees or affiliates. We are not responsible for the content of any third party posts or external links accessed through our social media channels.
Astellas EMEA reserves all rights relating to all of our social media channels as outlined below, including but not limited to:
- Modifying or removing any content posted on our channels by third parties
- Blocking other social media users
- Discontinuing the accounts at any time
As a responsible social media user, we monitor our social media channels daily but we do not commit to responding to every comment or mention. If you have an urgent question, you can contact us at [email protected].
The information provided on this website and our social media channels is not intended to be taken as medical advice. Please ensure that you consult with your healthcare professional regarding all personal medical or health-related issues.
Astellas Pharma Europe Ltd (“Astellas“) respects your right to privacy. For further information please refer to our privacy notice.
NPR/18/0044/APEL. February 2019